{
    "ucits": true,
    "type": "ETP",
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": false,
    "replication_method": "synthetic",
    "complex_factors": [
        "Leverage 5x exposure",
        "Use of derivatives integral to strategy",
        "Synthetic replication",
        "Daily leverage rebalancing and compounding effects",
        "Counterparty and collateral risk",
        "Complex payoff structure",
        "High risk rating (7/7)",
        "Lack of capital protection",
        "Potential illiquidity and early redemption risk"
    ],
    "classification": "complex",
    "supporting_data": "The product is a 5x leveraged long exposure to the S&P 500 index via an Exchange Traded Product (ETP) issued by Leverage Shares plc. It uses derivatives (swaps and margin accounts) as an integral part of its investment strategy to achieve 5 times the daily performance of the index, which is a hallmark of synthetic replication. The product documentation explicitly warns about the complexity of the product, including the compounding effect of daily leverage rebalancing, which can cause returns over periods longer than one day to deviate significantly from 5x the index return. The product carries a highest risk class (7/7), reflecting very high volatility and risk of loss, including the possibility of losing the entire investment. It is not capital protected and involves counterparty risk related to the collateral and swap counterparties. The product is intended for sophisticated investors with very short holding periods and understanding of leverage and derivatives. Under MiFID II Article 25(4)(a)(vi) and Commission Delegated Regulation Article 57, such use of derivatives integral to the strategy, leverage beyond UCITS limits, synthetic replication, and complex payoff profiles render the product complex. UCITS ETFs are generally non-complex, but this product is an ETP (not a UCITS ETF) and uses leverage and derivatives in a way that makes it complex. The product does not meet the criteria for non-complex instruments, such as absence of derivatives integral to the strategy, physical replication, or straightforward risk profiles. Therefore, it requires an appropriateness assessment before sale to retail clients under MiFID II. This classification aligns with ESMA guidance that synthetic ETFs, leveraged products, and those with embedded derivatives or complex structures are complex. The product also carries a mandatory comprehension alert in its KID, confirming its complex status."
}